Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2017 Results - Earnings Call Transcript

Nov. 01, 2017 2:04 PM ETMomenta Pharmaceuticals, Inc. (MNTA)
SA Transcripts profile picture
SA Transcripts

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Q3 2017 Earnings Conference Call November 1, 2017 10:00 AM ET


Sarah Carmody - Director, IR

Craig Wheeler - CEO, President and Executive Director

Scott Storer - CFO, Senior VP & Treasurer


Morgan Williams - Barclays PLC

Tyler Van Buren - Cowen and Company

Dana Flanders - Goldman Sachs Group

Thomas Shrader - Stifel, Nicolaus & Company

Gregory Gilbert - Deutsche Bank AG


Good day, ladies and gentlemen, and welcome to the Momenta Pharmaceuticals Third Quarter 2017 Earnings Call. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Sarah Carmody, Director of Investor Relations. Ma'am, you may begin.

Sarah Carmody

Thank you, Ashley, and good morning, everyone. Thank you for joining us today for Momenta's conference call to discuss results for the third quarter of 2017. Today's call is being webcast, and you can view the slides we will be presenting in the Investors section of our website at Joining me on the call with prepared remarks are Craig Wheeler, President and Chief Executive Officer; and Scott Storer, our Chief Financial Officer. Following our remarks, we will open the call to questions.

Before we begin, I'd like to mention that our call will contain forward-looking statements about our financial outlook, business plans and objectives and other future events and developments, including statements about the timing of regulatory filings; regulatory approvals; market formation and launches of our product candidates; the market potential of our products and product candidates; the Glatopa fill/finish manufacturer; legal proceedings time lines and strategic decisions; development of our product candidates, including timing of clinical trials and availability of data; the identity of our biosimilar candidates; accounting treatment for payments from our collaborators; our goal and strategy; our current and potential future collaborations; operating expense guidance; and spending projections.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.